The mechanism of action of platinum anticancer agents--what do we really know about it?
about
Redox activation of metal-based prodrugs as a strategy for drug deliverySynthesis, Characterization, and Interaction with Biomolecules of Platinum(II) Complexes with Shikimic Acid-Based Ligands.A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells.Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocyanates.The trans influence in the modulation of platinum anticancer agent biology: the effect of nitrite leaving group on aquation, reactions with S-nucleophiles and DNA binding of dinuclear and trinuclear compounds.Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexesComparative in vitro and in vivo pharmacological investigation of platinum(IV) complexes as novel anticancer drug candidates for oral application.In vitro and in vivo antitumor activities and DNA binding mode of five coordinated cyclometalated organoplatinum(II) complexes containing biphosphine ligands.Titanocene-phosphine derivatives as precursors to cytotoxic heterometallic TiAu2 and TiM (M = Pd, Pt) compounds. Studies of their interactions with DNATumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents.Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes.Overcoming biochemical pharmacologic mechanisms of platinum resistance with a texaphyrin-platinum conjugate.Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cellsOxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial PositionTuning the metabolism of the anticancer drug cisplatin with chemoprotective agents to improve its safety and efficacy.Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.Anticancer activity of metal complexes: involvement of redox processes.Polymeric biomaterials for the delivery of platinum-based anticancer drugs.Electrophoretic separation techniques and their hyphenation to mass spectrometry in biological inorganic chemistry.BODIPY-Appended 2-(2-Pyridyl)benzimidazole Platinum(II) Catecholates for Mitochondria-Targeted Photocytotoxicity.Platinum complexes as light promoted anticancer agents: a redefined strategy for controlled activation.Influence of self-assembly on intercalative DNA binding interaction of double-chain surfactant Co(III) complexes containing imidazo[4,5-f][1,10]phenanthroline and dipyrido[3,2-d:2'-3'-f]quinoxaline ligands: experimental and theoretical study.A cytotoxic and cytostatic gold(III) corrole.Cisplatin loaded methoxy poly (ethylene glycol)-block-Poly (L-glutamic acid-co-L-Phenylalanine) nanoparticles against human breast cancer cell.Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.Combating the drug resistance of cisplatin using a platinum prodrug based delivery system.Cytotoxic and antimicrobial activities of Cu(II), Co(II), Pt(II) and Zn(II) Complexes with N,O-chelating heterocyclic carboxylates.Interactions of oxaliplatin with the cytoplasmic thiol containing ligand glutathione.A relativistic DFT methodology for calculating the structures and NMR chemical shifts of octahedral platinum and iridium complexes.A systematic capillary electrophoresis study on the effect of the buffer composition on the reactivity of the anticancer drug cisplatin to the DNA model 2'-deoxyguanosine 5'-monophosphate (dGMP).N-acetyl-L-cysteine modulates the metabolism of cis-platin in human plasma in vitro.Citrate inhibition of cisplatin reaction with DNA studied using fluorescently labeled oligonucleotides: implication for selectivity towards guanine.An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents.In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS.Incorporation of cisplatin into the metal–organic frameworks UiO66-NH2 and UiO66 – encapsulation vs. conjugationMulti-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidneyNanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugsMetal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological ResearchMultivariant Crystallization of Tetraplatin Precursors from Solutions Containing 1,2-C6H10(NH3)2 2+ and [PtCl6]2– Ions
P2860
Q27025736-B9D65334-7C7D-454F-ADA1-79675E2A303AQ30607784-501AA9FE-B34D-48D4-9B92-CCF4DB6E941CQ33960795-8B3EF84D-DA07-47E0-9CDA-FB0A3FE6F94CQ34076604-47469447-6AB5-4C04-A561-7DF2C0A22A69Q34482184-AD4F7778-FFA1-4053-937C-5DCADFD54397Q34731239-2566E040-CD85-42C4-BA39-BA37516DD7BBQ35154374-3A399754-0FF3-41D9-98BF-5DDF08F1B537Q35216231-103480ED-E856-4DC0-9158-0BEFEE2E1F51Q35489393-F223C494-CD7F-43B2-899E-8D37629CCEFCQ35598162-3CB2817A-B251-4E34-9CED-5CE3E02D6E19Q36105474-D12D06F4-863F-4F8E-944A-B903E0948C2FQ36294083-823AE2CD-BB2E-403D-9ABF-A1D105FD41DDQ36890460-79234C44-CCC0-436D-A227-A1DDDADB17E7Q37087045-9497568F-5EC1-43B0-973E-824D4C43B81FQ37441359-77ADF5A6-A534-4BEE-8698-8CF86C625CAAQ37576021-6321A596-03DB-46EF-8197-7746044A0A04Q37833099-D24E862F-B2E2-432B-A4C1-320668573976Q38556758-0FA4360E-7267-467D-9607-3AB698F7C27CQ38661389-0A481AA3-0A38-4DFE-8FA5-E164A38333C0Q38755315-A0E15AC7-362A-4BBB-94BC-8F1E3373693BQ38791247-1D9CCB88-0438-442D-9FFA-5D1265DBB4E8Q38944113-37C9B456-4BA4-48D5-9994-548CDA80CE5EQ38953691-E86F9054-611E-4B9B-87CB-15AAA0613294Q38984345-7EF38BB0-53C9-4354-8C54-5B8A9CE9B2BEQ38993390-BAF27955-2B92-446D-9A5D-7FFF2F8C9111Q39341248-FCA357D3-598D-42C5-9AFE-F740D7F234E0Q39520245-162514E9-7D31-47EF-A2FE-0C33335CE863Q43485083-20F5FE66-787D-44FB-8726-2940437B6468Q43655859-10304F6E-D579-4B19-B228-8290C8671AAFQ44473824-79D3A80A-E3EC-4CAA-8463-ABDB7FF6D102Q45241480-68360066-9C52-4DE6-94AD-B41FADAEB99AQ45361492-18B0B668-6D88-433A-B24F-405D24B1F4CEQ49563999-8217C5B2-0467-4405-A4DB-A2F440EE09D3Q51307878-FCE1751B-EEA5-4FD1-BD48-6AF117CDD14FQ53116557-C4EF4744-3EF7-4B55-AF47-F8D34471489DQ57385191-D692F6C7-EA72-4381-BC7A-4381AF5A461AQ57900919-9867A054-4CF6-497A-861B-F90D49B70A85Q57900979-FD7EC2D7-36B5-44E3-8810-30F173094DEDQ58999393-39CB5092-E78C-4FDD-B4CB-F63F6E3B2258Q59145819-3C5601FD-B067-4B18-A0DF-474D4B739704
P2860
The mechanism of action of platinum anticancer agents--what do we really know about it?
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
The mechanism of action of platinum anticancer agents--what do we really know about it?
@en
The mechanism of action of platinum anticancer agents--what do we really know about it?
@nl
type
label
The mechanism of action of platinum anticancer agents--what do we really know about it?
@en
The mechanism of action of platinum anticancer agents--what do we really know about it?
@nl
prefLabel
The mechanism of action of platinum anticancer agents--what do we really know about it?
@en
The mechanism of action of platinum anticancer agents--what do we really know about it?
@nl
P2860
P356
P1433
P1476
The mechanism of action of platinum anticancer agents--what do we really know about it?
@en
P2093
Dan Gibson
P2860
P304
10681-10689
P356
10.1039/B918871C
P407
P577
2009-10-20T00:00:00Z